Source-grounded facts extracted from Gossamer Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Gossamer Bio, Inc. issued 135,789,000 Purchase Warrants of warrant to eligible holders of the Existing Convertible Notes for exchange of Existing Convertible Notes.
“the Company issued $65,174,000 in aggregate principal amount of New Convertible Notes, 254,150,441 shares of its Common Stock, 33,402,727 Prefunded Warrants and 135,789,000 Purchase Warrants to eligible holders of the Existing Convertible Notes accepted for exchange in the Exchange Offer.”
Gossamer Bio, Inc. issued 33,402,727 Prefunded Warrants of warrant to eligible holders of the Existing Convertible Notes for exchange of Existing Convertible Notes.
“the Company issued $65,174,000 in aggregate principal amount of New Convertible Notes, 254,150,441 shares of its Common Stock, 33,402,727 Prefunded Warrants and 135,789,000 Purchase Warrants to eligible holders of the Existing Convertible Notes accepted for exchange in the Exchange Offer.”
Gossamer Bio, Inc. issued 254,150,441 shares of common stock to eligible holders of the Existing Convertible Notes for exchange of Existing Convertible Notes.
“the Company issued $65,174,000 in aggregate principal amount of New Convertible Notes, 254,150,441 shares of its Common Stock, 33,402,727 Prefunded Warrants and 135,789,000 Purchase Warrants to eligible holders of the Existing Convertible Notes accepted for exchange in the Exchange Offer.”
Gossamer Bio, Inc. issued convertible note to eligible holders of the Existing Convertible Notes for $65,174,000 in aggregate principal amount.
“the Company issued $65,174,000 in aggregate principal amount of New Convertible Notes, 254,150,441 shares of its Common Stock, 33,402,727 Prefunded Warrants and 135,789,000 Purchase Warrants to eligible holders of the Existing Convertible Notes accepted for exchange in the Exchange Offer.”
Gossamer Bio, Inc. incurred convertible notes of $65,174,000 in aggregate principal amount of New Convertible Notes with U.S. Bank Trust Company, National Association at 7.50% per annum maturing July 1, 2030.
“the Company issued (i) $65,174,000 in aggregate principal amount of New Convertible Notes”
Gossamer Bio, Inc. entered into Purchase Warrant Agreement with Computershare, Inc., as warrant agent (effective 2026-06-04).
“a warrant agreement, dated as of June 4, 2026 (the “Purchase Warrant Agreement”), by and between the Company and Computershare, Inc., as warrant agent (the “Warrant Agent”).”
Gossamer Bio, Inc. entered into New Convertible Notes Indenture with U.S. Bank Trust Company, National Association, as trustee and collateral agent (effective 2026-06-04).
“an indenture, dated as of June 4, 2026 (the “New Convertible Notes Indenture”), by and between the Company, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee and collateral agent (in such capacity, the “Collateral Agent”).”
Gossamer Bio, Inc. shareholders approved Advisory approval of the compensation of the Company's named executive officers.
“The compensation of the named executive officers was approved, on an advisory basis, by the votes indicated: For Against Abstain Broker Non-Votes 111,286,550 7,545,502 137,461 45,450,098”
Gossamer Bio, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
“The selection was ratified by the votes indicated: For Against Abstain Broker Non-Votes 163,185,993 1,192,448 41,170 —”
Gossamer Bio, Inc. shareholders approved Election of two Class II directors for a three-year term to expire at the 2029 annual meeting.
“The following two Class II directors were re-elected by the votes indicated: For Withheld Broker Non-Votes Faheem Hasnain 92,301,637 26,667,876 45,450,098 Russell Cox 88,975,980 29,993,533 45,450,098”
Gossamer Bio, Inc. entered into Transaction Support Agreement with Supporting Noteholders valued at Certain beneficial owners or nominees, investment managers or advisors for beneficial holders of the (effective 2026-05-18).
“On May 18, 2026, the Company entered into a transaction support agreement (the "Transaction Support Agreement") with certain beneficial owners or nominees, investment managers or advisors for beneficial holders of the Existing Convertible Notes who hold approximately 75.2% of the aggregate principal amount of the Existing Convertible Notes (the "Supporting Noteholders").”
Gossamer Bio, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 18, 2026, the Company issued a press release reporting its financial results for the quarter ended March 31, 2026.”
Gossamer Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 8, 2026, Gossamer Bio, Inc. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), notifying the Company that, for the 30 consecutive business day period between February 24, 2026 through April 7, 2026, the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s w”
Gossamer Bio, Inc. reported the quarter and fiscal year ended December 31, 2025 results: net income Net loss for the three months ended December 31, 2025, was $47.2 million, or $0.21 per share, compared to a net loss of, EPS Net loss for the three months ended December 31, 2025, was $47.2 million, or $0.21 per share, compared to a net loss of.
“On March 17, 2026 , Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and fiscal year ended December 31, 2025.”
Gossamer Bio, Inc. issued up to approximately 6,688,964 additional shares of Common Stock of common stock to current stockholders of Prana and the former stockholders of Respira for cash and stock milestone payments upon the achievement of specified regulatory and sales milestones.
“upon the achievement of specified regulatory and sales milestones following the closing of the transaction, make cash and stock milestone payments, including the issuance of up to approximately 6,688,964 additional shares of Common Stock”
Gossamer Bio, Inc. issued up to an additional 1,500,000 shares of Common Stock of common stock to current stockholders of Prana and the former stockholders of Respira for following the exercise of the Company Merger Option at the closing of the transaction.
“agreed to (a) issue up to an additional 1,500,000 shares of Common Stock following the exercise of the Company Merger Option at the closing of the transaction”
Gossamer Bio, Inc. issued 2,500,000 shares of Common Stock of common stock to Prana Bio, Inc. for as consideration for the grant of the Company Merger Option.
“the Company (i) issued 2,500,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) to Prana on September 24, 2025 as consideration for the grant of the Company Merger Option and (ii) agreed to (a) issue up to an additional 1,500,000 shares of Common Stock following the exercise of the Company Merger Option at the closing of the transaction and (b) upon the achievement of specified regulatory and sales milestones following the closing of the transaction, make cash and stock milestone payments, including the issuance of up to approximately 6,688,964 additional shares of Common Stock”
Gossamer Bio, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $41.9 million, or $0.19 per share, EPS $0.19 per share.
“On May 7, 2024, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.”
Gossamer Bio, Inc. entered into Chiesi Collaboration Agreement with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, Chiesi) valued at Upfront payment of $160 million, plus up to $146 million in regulatory milestones and $180 million i (effective 2024-05-03).
“On May 3, 2024, Gossamer Bio, Inc. (“Gossamer” or the “Company”), GB002, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“GB002”), and Gossamer Bio 002 Ltd., a corporation organized and existing under the laws of Ireland and indirect wholly-owned subsidiary of the Company, entered into a global collaboration and license agreement (the “Chiesi Collaboration Agreement”) with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, “Chiesi”). The collaboration is focused on the development and commercialization of seralutinib and licensed products including seralutinib and related licensed compounds (“Licensed Products”) in the US (“US Territory”) and the rest of the world (“ROW Territory”), for therapeutic, prophylactic and diagnostic uses in humans and animals, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) and other indications, as may be permitted under the Chiesi Co”
Steven Nathan was appointed as Class I director at Gossamer Bio, Inc..
“Steven Nathan, M.D. to serve as a Class I director effective March 11, 2024”
Skye Drynan was appointed as Class III director at Gossamer Bio, Inc..
“appointed Skye Drynan to serve as a Class III director effective March 11, 2024”
Gossamer Bio, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 5, 2024 , Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and fiscal year ended December 31, 2023.”
John Quisel was appointed as Class III Director at Gossamer Bio, Inc..
“the Board appointed John Quisel, J.D., Ph.D. to serve as a Class III director”
Gossamer Bio, Inc.: Amended and restated bylaws to address universal proxy rules and enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals (effective 2023-11-27).
“On November 27, 2023, the Board of Directors (the "Board") of the Company approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective the same day.”
Gossamer Bio, Inc. reported third quarter ended September 30, 2023 results: net income $40.0 million, or $0.21 per share, EPS $0.21 per share.
“Net loss for the quarter ended September 30, 2023, was $40.0 million, or $0.21 per share, compared to a net loss of $59.4 million, or $0.65 per share, for the same period in 2022.”
Gossamer Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“hrough October 18, 2023, the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s written notice does not result in the immediate delisting of the Common Stock from the Nasdaq Global Market In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has 180 calendar days, or until April 16, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.”
Kristina Burow resigned as Director at Gossamer Bio, Inc..
“On September 6, 2023, Kristina Burow resigned from the Board of Directors (the “Board”) of Gossamer Bio, Inc. (the "Company").”
Gossamer Bio, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share, EPS $0.45 per share.
“On August 8, 2023, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.”
Gossamer Bio, Inc. entered into Purchase Agreement with purchasers named therein, including certain directors and executive officers of the Company valued at approximately $212.1 million (effective 2023-07-19).
“On July 19, 2023, Gossamer Bio, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein, including certain directors and executive officers of the Company (the “Purchasers”), for the private placement (the “Private Placement”) of 129,869,440 shares”
Gossamer Bio, Inc.: Amendment to certificate of incorporation to eliminate personal liability of officers for monetary damages for breach of fiduciary duty as an officer (effective 2023-06-08).
“On June 8, 2023, Gossamer Bio, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, as described below under Item 5.07, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, to eliminate the personal liability of the Company’s officers for monetary damages for breach of fiduciary duty as an officer, except to the extent such an exemption from liability or limitation thereof is not permitted by Delaware General Corporation Law (the “Amendment”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware on June 8, 2023 (“Certificate of Amendment”).”
Gossamer Bio, Inc. shareholders approved Approval of an amendment to our Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company. at the 2023-06-08 meeting.
“The approval of an amendment to our Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company by the votes indicated: For Against Abstain Broker Non-Votes 55,967,264 2,924,078 73,260 17,454,308”
Gossamer Bio, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers. at the 2023-06-08 meeting.
“The approval, on an advisory basis, of the compensation of the Company's named executive officers. The compensation of the named executive officers was approved, on an advisory basis, by the votes indicated: For Against Abstain Broker Non-Votes 38,901,355 19,975,931 87,316 17,454,308”
Gossamer Bio, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-08 meeting.
“The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The selection was ratified by the votes indicated: For Against Abstain Broker Non-Votes 76,279,156 72,683 67,071 —”
Gossamer Bio, Inc. shareholders approved Election of two directors to serve as Class II directors for a three-year term to expire at the 2026 annual meeting of stockholders. at the 2023-06-08 meeting.
“The election of two directors to serve as Class II directors for a three-year term to expire at the 2026 annual meeting of stockholders. The following two Class II directors were re-elected by the votes indicated: For Withheld Broker Non-Votes Faheem Hasnain 53,389,848 5,574,754 17,454,308 Russell Cox 42,130,560 16,834,042 17,454,308”
Gossamer Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023, was $49.2 million, or $0.52 per share.
“On May 9, 2023, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2023.”
Gossamer Bio, Inc. reported the full year ended December 31, 2022 results: net income Net loss for the full year ended December 31, 2022, was $229.4 million, EPS $2.71 per share.
“Net loss for the full year ended December 31, 2022, was $229.4 million, or $2.71 per share”
Gossamer Bio, Inc. reported the three months ended December 31, 2022 results: net income Net loss for the three months ended December 31, 2022, was $55.8 million, EPS $0.59 per share.
“Net loss for the three months ended December 31, 2022, was $55.8 million, or $0.59 per share”
Gossamer Bio, Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022, was $59.4 million, or $0.65 per share, EPS $0.65 per share.
“Gossamer Bio, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2022.”
Bryan Giraudo changed role as Chief Operating Officer/Chief Financial Officer at Gossamer Bio, Inc..
“Effective September 16, 2021, Bryan Giraudo was promoted to Chief Operating Officer/Chief Financial Officer of Gossamer Bio, Inc.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.